Uncategorized
Tocilizumab shows positive results for giant cell arteritis in phase 3 trial
In a phase 3 trial, tocilizumab showed positive phase 3 trial results for patients with giant cell arteritis.“The publication of these phase 3 results in The New England Journal of Medicine validates the significance of our considerable basic and clinical autoimmune disease research in medical practice,” Sandra Horning, MD, chief medical officer and head of Global Product Development, said in a press release from Genentech. “The data from the GiACTA supported the FDA approval of the first new treatment option for patients with [giant cell arteritis] GCA in more than (Read more...)